Related Experiment Video
Updated: Aug 9, 2026
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma
Francesco Leone1, Giuliana Cavalloni, Ymera Pignochino
1Department of Clinical Oncology, Unit of Pathology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy. francesco.leone@ircc.it
Objective:
Conventional therapies are still unsuccessful in patients with carcinoma arising from the biliary tract. Somatic mutations of the epidermal growth factor receptor (EGFR) gene and the activation of its downstream pathways predict the sensitivity to small-molecule inhibitors in non-small cell lung carcinoma. Therefore, we analyzed EGFR mutations and related pathways in gallbladder and bile duct carcinomas to consider the possible application of these alternative therapeutic strategies.
Experimental Design:
Forty paraffin-embedded samples, including intrahepatic or extrahepatic cholangiocarcinoma and gallbladder carcinoma, were studied after tumor cell isolation by laser microdissection and sequencing of EGFR tyrosine kinase domain (exons 18-21). Activation of EGFR pathway was studied by evaluating phosphorylation of mitogen-activated protein kinase and Akt.
Results:
None of the 40 specimens had mutations in exon 18; one had one missense point mutation in exon 19, two in exon 20, and three in exon 21. In addition, 36 of 40 specimens had the same silent mutation at codon 787 in exon 20, which was also found in peripheral blood cells from healthy donors. Tumor samples harboring EGFR mutation had phosphorylation of one or both downstream transducers analyzed.
Conclusions:
This is the first evidence of somatic mutations of the EGFR gene in bile duct carcinoma. Our findings suggest that a subgroup of patients with cholangiocarcinoma or gallbladder carcinoma exhibits somatic mutations of EGFR in the tyrosine kinase domain that can elicit cell signals sustaining survival and proliferation. These tumors might be further evaluated for their susceptibility to small-molecule inhibitor treatment.
Insights
EGFR mutations were found in some biliary tract cancers, suggesting potential sensitivity to targeted therapies. This research explores new treatment avenues for gallbladder and bile duct carcinomas.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Biliary tract carcinomas, including gallbladder and bile duct cancers, have limited treatment options.
- Epidermal growth factor receptor (EGFR) mutations are key in non-small cell lung cancer treatment.
- Investigating EGFR in biliary cancers may reveal new therapeutic targets.
Purpose of the Study:
- To analyze EGFR mutations and pathway activation in gallbladder and bile duct carcinomas.
- To explore the potential of small-molecule inhibitors for biliary tract cancers.
Main Methods:
- Sequencing of the EGFR tyrosine kinase domain (exons 18-21) in 40 tumor samples.
- Analysis of EGFR pathway activation via mitogen-activated protein kinase and Akt phosphorylation.
- Tumor cells isolated using laser microdissection from paraffin-embedded samples.
Main Results:
- EGFR mutations were detected in 7 out of 40 biliary tract cancer specimens.
- A silent mutation at codon 787 in exon 20 was common and also found in healthy donors.
- Tumors with EGFR mutations showed activation of downstream signaling pathways.
Conclusions:
- This study provides the first evidence of somatic EGFR mutations in bile duct carcinoma.
- A subset of biliary tract cancers harbors EGFR mutations that promote cell survival and proliferation.
- These findings support further evaluation of small-molecule inhibitors for treating biliary tract cancers.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal